Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era
Hematology (Amsterdam, Netherlands) | 14 Mar 2014
AH Zaky, R Bakry, MI El-sayed, MA Elwanis and O Nabih
NOVELTY AND IMPACT: This first study compares the survival of HCV-positive DLBCL treated with and without rituximab which showed in toxicity and the outcome.
* Data courtesy of Altmetric.com